Gates-backed Affinivax grabs $10M upfront and a major league partner for a groundbreaking attempt to beat Pfizer’s superstar vaccine
Over the past three years Steve Brugger and the crew at Cambridge, MA-based Affinivax have been working steadily on a next-gen platform for vaccine development, laying the groundwork — with key support from the Bill & Melinda Gates Foundation — for the first clinical trial of what they believe can be a breakthrough in the vaccines field.
This morning, Brugger is unveiling a collaboration with Astellas, which had earlier signed on to collaborate on a very early-stage vaccine program at the biotech. Now Astellas has come in with $10 million to front their pact on the lead effort, signing off on an undisclosed set of milestones and royalties while agreeing to shoulder the full cost of the clinical program that lies ahead.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.